Submission of Monitoring Agency Report issued by ICRA Limited for the quarter ended June 30, 2025.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare Solutions has submitted the ICRA Monitoring Agency Report on the use of its IPO proceeds (raised in February 2024, net proceeds of ₹951.33 crores). ICRA confirmed that there is no deviation from the stated objects of the issue. As of June 30, 2025, the company has utilized ₹879.78 crores (about 92.5%) of the net proceeds across four approved purposes: repayment of borrowings (₹142.50 cr, fully completed), funding working capital (₹428.45 cr of ₹480 cr, ₹51.55 cr remaining), inorganic growth via acquisitions (₹237 cr, fully completed), and general corporate purposes (₹71.83 cr of ₹91.83 cr, ₹20 cr remaining). The remaining ₹71.55 crores of unutilized funds are parked in fixed deposits with Axis Bank and ICICI Bank, and in current accounts. All objects are on schedule with no delays or unfavorable events reported.
This is a routine regulatory filing confirming disciplined deployment of IPO funds with no diversions or red flags. For shareholders, the clean report should provide reassurance on governance, while the completed acquisition spending suggests capital deployment is on track, though nearly ₹72 crores still sits idle earning modest returns in bank deposits.